JPWO2021132592A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021132592A5 JPWO2021132592A5 JP2021567688A JP2021567688A JPWO2021132592A5 JP WO2021132592 A5 JPWO2021132592 A5 JP WO2021132592A5 JP 2021567688 A JP2021567688 A JP 2021567688A JP 2021567688 A JP2021567688 A JP 2021567688A JP WO2021132592 A5 JPWO2021132592 A5 JP WO2021132592A5
- Authority
- JP
- Japan
- Prior art keywords
- swi
- snf complex
- cancer
- complex factor
- suppression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 25
- 201000011510 cancer Diseases 0.000 claims 25
- 238000000034 method Methods 0.000 claims 14
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 claims 10
- 102100023410 Phospholipid hydroperoxide glutathione peroxidase Human genes 0.000 claims 10
- 230000001629 suppression Effects 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 239000012830 cancer therapeutic Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 102100034580 AT-rich interactive domain-containing protein 1A Human genes 0.000 claims 2
- 102100034571 AT-rich interactive domain-containing protein 1B Human genes 0.000 claims 2
- 102100023157 AT-rich interactive domain-containing protein 2 Human genes 0.000 claims 2
- 102100022983 B-cell lymphoma/leukemia 11B Human genes 0.000 claims 2
- 101000924266 Homo sapiens AT-rich interactive domain-containing protein 1A Proteins 0.000 claims 2
- 101000924255 Homo sapiens AT-rich interactive domain-containing protein 1B Proteins 0.000 claims 2
- 101000685261 Homo sapiens AT-rich interactive domain-containing protein 2 Proteins 0.000 claims 2
- 101000903697 Homo sapiens B-cell lymphoma/leukemia 11B Proteins 0.000 claims 2
- 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 claims 2
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 claims 2
- 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 claims 2
- 102100031027 Transcription activator BRG1 Human genes 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000004777 loss-of-function mutation Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 230000009454 functional inhibition Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025136970A JP2025164846A (ja) | 2019-12-26 | 2025-08-20 | Ｇｐｘ４阻害剤に対するがん細胞の感受性を予測する方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019236516 | 2019-12-26 | ||
| PCT/JP2020/048811 WO2021132592A1 (ja) | 2019-12-26 | 2020-12-25 | Ｇｐｘ４阻害剤に対するがん細胞の感受性を予測する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025136970A Division JP2025164846A (ja) | 2019-12-26 | 2025-08-20 | Ｇｐｘ４阻害剤に対するがん細胞の感受性を予測する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2021132592A1 JPWO2021132592A1 (https=) | 2021-07-01 |
| JPWO2021132592A5 true JPWO2021132592A5 (https=) | 2023-12-27 |
Family
ID=76574718
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021567688A Pending JPWO2021132592A1 (https=) | 2019-12-26 | 2020-12-25 | |
| JP2025136970A Pending JP2025164846A (ja) | 2019-12-26 | 2025-08-20 | Ｇｐｘ４阻害剤に対するがん細胞の感受性を予測する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025136970A Pending JP2025164846A (ja) | 2019-12-26 | 2025-08-20 | Ｇｐｘ４阻害剤に対するがん細胞の感受性を予測する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US12529701B2 (https=) |
| EP (1) | EP4082575A4 (https=) |
| JP (2) | JPWO2021132592A1 (https=) |
| CN (1) | CN114555122A (https=) |
| WO (1) | WO2021132592A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11541116B1 (en) | 2022-01-07 | 2023-01-03 | Kojin Therapeutics, Inc. | Methods and compositions for inducing ferroptosis in vivo |
| CN116004644A (zh) * | 2023-01-19 | 2023-04-25 | 南京中澳转化医学研究院有限公司 | Smarca4突变体及其在结直肠癌药物开发中的应用 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN117625604A (zh) * | 2023-11-02 | 2024-03-01 | 江南大学 | 基因prdx5和gpx4在制备去势抵抗性前列腺癌的药物中的应用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025263619A1 (ja) * | 2024-06-20 | 2025-12-26 | 学校法人日本医科大学 | グルタチオン代謝関連酵素阻害剤に対するがんの感受性予測方法 |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
| EP3630089A4 (en) * | 2017-05-24 | 2021-06-09 | Ferro Therapeutics, Inc. | PROCEDURE FOR CANCER THERAPY |
| EP3645739A4 (en) * | 2017-06-28 | 2021-07-14 | The Regents of the University of California | METHODS AND COMPOSITIONS FOR TREATMENT OF MELANOMA |
-
2020
- 2020-12-25 EP EP20906713.1A patent/EP4082575A4/en active Pending
- 2020-12-25 US US17/785,484 patent/US12529701B2/en active Active
- 2020-12-25 JP JP2021567688A patent/JPWO2021132592A1/ja active Pending
- 2020-12-25 CN CN202080071348.3A patent/CN114555122A/zh active Pending
- 2020-12-25 WO PCT/JP2020/048811 patent/WO2021132592A1/ja not_active Ceased
-
2025
- 2025-08-20 JP JP2025136970A patent/JP2025164846A/ja active Pending
- 2025-12-11 US US19/415,883 patent/US20260098862A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021132592A5 (https=) | ||
| Hayes et al. | Oxidative stress in cancer | |
| Ahangari et al. | Saracatinib, a selective Src kinase inhibitor, blocks fibrotic responses in preclinical models of pulmonary fibrosis | |
| Abida et al. | Genomic correlates of clinical outcome in advanced prostate cancer | |
| Perrotti et al. | Chronic myeloid leukemia: mechanisms of blastic transformation | |
| Naqvi et al. | Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic‐phase chronic myeloid leukemia | |
| Ott et al. | A phase II trial of sorafenib in metastatic melanoma with tissue correlates | |
| Blecua et al. | The DNA methylation landscape of hematological malignancies: an update | |
| Taylor-Harding et al. | Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS | |
| Gatto et al. | The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate | |
| Benamar et al. | Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma | |
| Chandarlapaty | Negative feedback and adaptive resistance to the targeted therapy of cancer | |
| Solit et al. | Towards a unified model of RAF inhibitor resistance | |
| Nissan et al. | ERK pathway inhibitors: how low should we go? | |
| Zeng et al. | The phosphatidylinositol 3-kinase pathway as a potential therapeutic target in bladder cancer | |
| Ma et al. | Effect evaluation of cisplatin-gemcitabine combination chemotherapy for advanced non-small cell lung cancer patients using microarray data. | |
| Brambullo et al. | Xeroderma pigmentosum: A genetic condition skin cancer correlated—A systematic review | |
| Kim et al. | OCT-1, ABCB1, and ABCG2 expression in imatinib-resistant chronic myeloid leukemia treated with dasatinib or nilotinib | |
| Stainczyk et al. | Neuroblastoma—Telomere maintenance, deregulated signaling transduction and beyond | |
| Lim et al. | Targeting the PI3K/PTEN/AKT/mTOR pathway in treatment of sarcoma cell lines | |
| Slipicevic et al. | Narrowing the knowledge gaps for melanoma | |
| Peterson et al. | Induction of p53 suppresses chronic myeloid leukemia | |
| Takai et al. | Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma | |
| Chereda et al. | The biology and pathogenesis of chronic myeloid leukemia | |
| Min et al. | The role of clonal haematopoiesis in cardiovascular diseases: epidemiology and experimental studies |